SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cytori Therapeutics, Inc.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tnsaf5/29/2009 12:55:44 AM
   of 251
 
Cytori Reports Publication of Cardiovascular Preclinical Study; Adipose Stem & Regenerative Cells Improve Function in Heart Attack Model

SAN DIEGO, May 28, 2009 (BUSINESS WIRE) -- Cytori (NASDAQ: CYTX) announced publication of the first preclinical study to demonstrate adipose-derived stem and regenerative cells (ADRCs) significantly improved cardiac function after a heart attack. This preclinical cardiac cell therapy study was reported online ahead of print in the International Journal of Cardiology. The study was funded by Cytori Therapeutics and conducted at Tulane University.

"Treatment of cardiovascular disease, which places one of the greatest burdens on our healthcare system, could be revolutionized by cell therapy," said Marc H. Hedrick, M.D., president of Cytori. "We observed a statistically significant improvement in heart function that contributed to our decision to proceed with our APOLLO study. Cardiovascular disease is the most advanced application in Cytori's product pipeline and could eventually make a substantial contribution to our future commercial activities."

The APOLLO study is the first clinical trial to investigate uncultured adipose-derived stem and regenerative cells in heart attacks in human patients. Enrollment was recently completed in APOLLO, a double blind, placebo controlled, safety and feasibility trial. Data are expected to be reported in early 2010. The APOLLO study is sponsored by Cytori and has incorporated the Company's Celution(R) System to automate the processing of the patients' cells at the point of care.

In Cytori's preclinical study, 17 large animals (pigs) were treated with their own uncultured adipose-derived stem and regenerative cells immediately following induction of a severe myocardial infarction. Uncultured cells include a multitude of heterogeneous cell types that Cytori believes facilitate several therapeutic mechanisms. Several functional measurements within the study indicated statistically significant improvement in both heart function and structure. The results are summarized in the table below.

   Measurement          Cells       Control   Improvement    p
  Perfusion Defect     35 ± 9%      44 ± 5%       20%      <0.05
    % decrease

  Ejection Fraction    43 ± 7%      35 ± 3%       19%      <0.05
    % increase

Heart Wall Thickness 11.2 ± 2.2    8.6 ± 1.6      23%      <0.05 
         mm

  Capillary Density  41.6 ± 17.9  32.9 ± 12.6     21%      <0.05
     per 0.1 mm2
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News